Cite
CHRONOS‐3: Randomized phase III study of copanlisib plus rituximab/placebo in relapsed indolent Non-Hodgkin Lymphoma (INHL)
MLA
Zinzani, P. L., et al. “CHRONOS‐3: Randomized Phase III Study of Copanlisib plus Rituximab/Placebo in Relapsed Indolent Non-Hodgkin Lymphoma (INHL).” Zinzani, P.L., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., Sapunarova, K., Lin, T., Jin, J., Jurczak, W., Hamed, A., Wang, M.C., Baker, R. <, 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1276819141&authtype=sso&custid=ns315887.
APA
Zinzani, P. L., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., Sapunarova, K., Lin, T., Jin, J., Jurczak, W., Hamed, A., Wang, M. C., Baker, R., Bondarenko, I., Zhang, Q., Feng, J., Geissler, K., Lazaroiu, M., Saydam, G., … Matasar, M. J. (2021). CHRONOS‐3: Randomized phase III study of copanlisib plus rituximab/placebo in relapsed indolent Non-Hodgkin Lymphoma (INHL). Zinzani, P.L., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., Sapunarova, K., Lin, T., Jin, J., Jurczak, W., Hamed, A., Wang, M.C., Baker, R. <.
Chicago
Zinzani, P.L., M. Capra, M. Özcan, F. Lv, W. Li, E. Yañez, K. Sapunarova, et al. 2021. “CHRONOS‐3: Randomized Phase III Study of Copanlisib plus Rituximab/Placebo in Relapsed Indolent Non-Hodgkin Lymphoma (INHL).” Zinzani, P.L., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., Sapunarova, K., Lin, T., Jin, J., Jurczak, W., Hamed, A., Wang, M.C., Baker, R. <. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1276819141&authtype=sso&custid=ns315887.